AbbVie touts Qulipta chronic migraine win as Biohaven duel heats up

Oral CGRP inhibitors made by AbbVie and Biohaven Pharmaceuticals are quickly gaining share in the migraine market. But unlike their injectable peers, the two oral options have their prevention labels limited to episodic patients. That might change soon.